Mass Tort & MDL Plaintiff Funding in New Jersey

New Jersey applies a two-year limitations period to a mass tort claim (N.J.S.A. 2A:14-2), governing the timing of a claim brought under the New Jersey Products Liability Act (N.J.S.A. 2A:58C-1 et seq.). New Jersey's common-law discovery rule — established in Lopez v. Swyer, 62 N.J. 267 (1973) — delays accrual until the plaintiff discovers, or reasonably should discover, facts sufficient to support a viable cause of action, a doctrine frequently applied in New Jersey's substantial mass tort docket. New Jersey does not have a general statute of repose for ordinary consumer products.

New Jersey applies modified comparative fault with a 51% bar under its Comparative Negligence Act (N.J.S.A. 2A:15-5.1). The New Jersey Products Liability Act separately defines the limited defenses available to a manufacturer, including compliance with government safety standards and, for certain products, an inherent-characteristics defense (N.J.S.A. 2A:58C-3) — defenses that frequently feature in the causation and general-liability disputes litigated during a New Jersey mass tort's early bellwether phase.

New Jersey has no general statutory cap on compensatory damages applicable to a mass tort claim.

New Jersey mandates pre-judgment interest on tort judgments under Court Rule 4:42-11(b), calculated from the date the cause of action arose with limited exceptions; a claim resolved through the Multicounty Litigation program's global settlement instead receives an allocated award under the settlement's own terms.

A New Jersey mass tort claim filed in or removable to federal court can be transferred to a federal MDL under 28 U.S.C. §1407 for coordinated pretrial proceedings. New Jersey is also home to one of the most prominent state-level mass tort coordination programs in the country: its Multicounty Litigation (MCL) program, administered under New Jersey Court Rule 4:38A before designated MCL judges (most often sitting in Atlantic, Bergen, or Middlesex County), has coordinated a large share of the nation's major pharmaceutical and consumer-product mass torts, frequently running in parallel with a corresponding federal MDL over the same underlying tort.

New Jersey has no dedicated consumer litigation funding statute. No statutory cap.

Why is New Jersey's Multicounty Litigation program significant for a mass tort funding decision?

New Jersey's MCL program has coordinated some of the largest pharmaceutical and consumer-product mass torts in the country, often running in parallel with a federal MDL over the identical underlying tort, which means a New Jersey-filed claim frequently benefits from two coordinated proceedings developing causation science and settlement frameworks simultaneously.

For funding purposes, confirming whether a specific plaintiff's claim is enrolled in the MCL, the federal MDL, or both is important, since settlement timing and terms can differ somewhat between the parallel state and federal tracks even for the same underlying mass tort, and the MCL's own bellwether and settlement history is often the more directly relevant data point for a New Jersey-filed claim.

How does New Jersey's mandatory pre-judgment interest affect a mass tort case that proceeds to individual trial?

Because pre-judgment interest is mandatory in New Jersey and runs from when the cause of action arose, an individual New Jersey mass tort bellwether case that proceeds to verdict accrues value more predictably over time than the equivalent case in a state where pre-judgment interest is discretionary or unavailable.

This is most relevant to a bellwether plaintiff or an opt-out claimant pursuing individual litigation rather than a global settlement, and it is a meaningful factor in valuing that specific track of a New Jersey mass tort relative to the settlement-matrix track most enrolled plaintiffs will use instead.